Armistice Capital LLC Boosts Holdings in Moleculin Biotech, Inc. (NASDAQ:MBRX)

Armistice Capital LLC grew its position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) by 5.1% in the second quarter, Holdings Channel reports. The institutional investor owned 156,000 shares of the company’s stock after buying an additional 7,505 shares during the period. Armistice Capital LLC owned 0.07% of Moleculin Biotech worth $549,000 as of its most recent filing with the SEC.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Moleculin Biotech in a research note on Thursday. They set a “sell” rating on the stock.

Moleculin Biotech Stock Performance

Moleculin Biotech stock opened at $2.44 on Friday. The stock’s 50 day moving average price is $2.68 and its 200 day moving average price is $4.10. Moleculin Biotech, Inc. has a 1-year low of $2.12 and a 1-year high of $15.75.

Moleculin Biotech (NASDAQ:MBRX) last issued its earnings results on Tuesday, August 13th. The company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($2.10) by ($0.13). As a group, sell-side analysts forecast that Moleculin Biotech, Inc. will post -8.6 EPS for the current fiscal year.

Moleculin Biotech Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.